Repros Therapeutics Inc. Provides Clinical Update for Androxal(R) Study in Men With Type 2 Diabetes

THE WOODLANDS, Texas, May 2, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a progress update for its Phase 2 clinical study of Androxal® in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism are also type 2 diabetic. The Company noted that 66 subjects have been randomized into the trial that is being conducted at 19 clinical sites in the US. The Company intends to conduct an interim analysis per the trial protocol when 60 subjects complete the three-month study. Based on the current enrollment rate Repros believes the interim results will be available in September of this year and that the study will be fully enrolled at that time (120-150 subjects). Top line results for the full study should be available around year end 2011.